We are proud to announce that Sulfateq B.V. received a Samenwerkingsverband Noord-Nederland (SNN) Valorisation grant for the development of SUL-138 as Acute Kidney Injury (AKI) prophylaxis. This grant helps us to continue the development that was already stimulated by SNN in the EFRO Tender Valorisation.

The Valorisation grant enables Sulfateq B.V. to accelerate the remaining preclinical safety program for SUL-138. This compound shows great potential as preventive treatment against AKI, which is a serious condition characterized by a rapid deterioration in kidney function. Currently, there are no specific therapies that preclude or attenuate AKI thus it is an unmet clinical need. Sulfateq B.V. is highly motivated to get SUL-138 to the clinic where it is so desperately needed and the Northern Netherlands represents an excellent environment for achieving this ambition.

For more information or questions, please contact us via the contact form.